A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Clinical trial NCT07424404 · RECRUITING
Trial details
- NCT number
- NCT07424404
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-07
- Primary completion
- 2030-03-08
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.